IGDRASOL THERAPEUTICS
Focusing on the development of oncologic agents for the treatment for cancers
IGDRASOL THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Biotherapies
Biotherapies, Inc. is dedicated to the development of better cancer treatment and diagnosis.
Famous Biotech
focus on the development of anticancer small molecule
Fast BioPharma
Fast BioPharma Ltd. develops therapeutic products for treatment of cancer.
Hermes Biosciences
HERMES Biosciences, Inc. engages in the development of targeted drug delivery technologies for therapeutics.
Mabpharm Private Ltd
Mabpharm is engaged in development of monoclonal antibodies for treatment of cancer and auto-immune diseases.
Pharmagap Inc.
Pharmagap is a company that develops therapeutic drugs for the treatment of cancer.
ScandiBio Therapeutics
We develop metabolic co-factors that can be used in treatment of metabolic diseases.
Umut Biotechnology
Population and ethnicity specific genetic risk assessment test using DNA biomarkers for breast cancer.
WeMED Bio-Tech Inc.
Research and development of medical devices targeted at unmet needs
Founder
More informations about "Igdrasol Therapeutics"
Sorrento Therapeutics Completes IgDraSol Merger - PR Newswire
SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that it has completed the merger with IgDraSol, Inc., a privately …See details»
Sorrento Therapeutics Completes IgDraSol Merger
The acquisition of IgDraSol bolsters our leadership team with highly relevant and successful experience in developing and commercializing cancer therapeutics, including Abraxane ®. We …See details»
OTLC - Oncotelic Therapeutics, Inc. | Company Profile | OTC Markets
Mar 13, 2025 He also served as President and CEO of IgDraSol, Inc. beginning in 2012 until its acquisition by Sorrento Therapeutics, Inc. in 2013. ... View company information for Oncotelic …See details»
Igdrasol Therapeutics - Crunchbase Company Profile & Funding
Organization. Igdrasol Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. ... Who are Igdrasol Therapeutics 's competitors? …See details»
EX-2.1 - SEC.gov
Sep 9, 2013 the stockholders of IgDraSol, Inc.; and . VUONG TRIEU, ... 2013, by and among: Sorrento Therapeutics, Inc., ... 4.1 Due Organization; Etc. (a) Each of Parent and Merger Sub …See details»
8-K - SEC.gov
Sep 9, 2013 SORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware : 000-52228 : 33-0344842 (State or other jurisdiction of. incorporation or …See details»
Sorrento Therapeutics
Responsible for building Abraxis commercial organization George Uy CCO CCO of IgDraSol Directed the launches of Abraxane, Xeloda ® & Fusilev Built commercial infrastructures and …See details»
Sorrento Therapeutics, Inc. Completes IgDraSol Merger
Sep 10, 2013 The acquisition of IgDraSol bolsters our leadership team with highly relevant and successful experience in developing and commercializing cancer therapeutics, including …See details»
Sorrento Therapeutics, Inc. and IGDRASOL Announce Three …
Mar 31, 2013 SAN DIEGO and FOUNTAIN VALLEY, Calif., March 31, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("STI"; SRNE) and IGDRASOL announced today that IGDRASOL …See details»
Sorrento Therapeutics signs exclusive option to acquire IGDRASOL
Mar 8, 2013 USA-based Sorrento Therapeutics, Inc. (SRNE: OB) has signed an exclusive option to acquire IGDRASOL, a private company focused on the development of oncologic agents for …See details»
Sorrento Therapeutics, Inc. and IGDRASOL Announce the …
May 13, 2013 SAN DIEGO and IRVINE, Calif., May 13, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("STI"; SRNE) and IGDRASOL announced today the acquisition of …See details»
Igdrasol Therapeutics - Crunchbase
Focusing on the development of oncologic agents for the treatment for cancersSee details»
IgDraSol - Products, Competitors, Financials, Employees, …
5/15/2015 7:26:09 AM NantWorks Acquires Cynviloqâ„¢ For Up To $1.3+ Billion SAN DIEGO, May 15, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), …See details»
NantPharma to buy Sorrento’s Igdrasol - Pharmaceutical Technology
May 17, 2015 NantPharma to buy Sorrento’s Igdrasol. NantWorks ecosystem of companies member NantPharma has agreed to acquire a wholly owned subsidiary of Sorrento, Igdrasol, …See details»
NantPharma, LLC completed the acquisition of IgDraSol Inc. from ...
Jul 8, 2015 NantPharma, LLC entered into agreement to acquire IgDraSol Inc. from Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) for approximately $1.3 billion on May 14, 2015. Under …See details»
Sorrento Therapeutics, Inc. Completes IgDraSol Merger
SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that it has completed the merger with IgDraSol, Inc., a privately …See details»
Sorrento Therapeutics, Inc. and IGDRASOL Will Present ... - Medindia
Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and IGDRASOL announced today that the companies will present Phase III interim data analysis of Cynviloq in metastatic breast cancer …See details»
Sorrento Therapeutics and IGDRASOL Proceed with Development …
Aug 5, 2013 Sorrento Therapeutics and IGDRASOL Proceed with Development of Cynviloqâ„¢ under 505(b)(2) Bioequivalence Regulatory Pathway Official Minutes from End-of-Phase 2 …See details»
NantWorks gains rights to Sorrento's cancer therapy Cynviloq for …
NantWorks subsidiary NantPharma reached an agreement to acquire Sorrento Therapeutics' Igdrasol unit, obtaining rights to the experimental cancer treatment Cynviloq (paclitaxel …See details»
EX-99.1 - SEC.gov
But it is also developing therapeutics products for other indications, including inflammation, metabolic, and infectious diseases. Sorrento Therapeutics’ proprietary G-MAB ® fully-human …See details»